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Abstract
Background: New, more effective strategies are needed to treat highly aggressive neuroblastoma. Our laboratory has 
previously shown that full-length Secreted Protein Acidic and Rich in Cysteine (SPARC) and a SPARC peptide 
corresponding to the follistatin domain of the protein (FS-E) potently block angiogenesis and inhibit the growth of 
neuroblastoma tumors in preclinical models. Peptide FS-E is structurally complex and difficult to produce, limiting its 
potential as a therapeutic in the clinic.
Results: In this study, we synthesized two smaller and structurally more simple SPARC peptides, FSEN and FSEC, that 
respectively correspond to the N-and C-terminal loops of peptide FS-E. We show that both peptides FSEN and FSEC 
have anti-angiogenic activity in vitro and in vivo, although FSEC is more potent. Peptide FSEC also significantly inhibited 
the growth of neuroblastoma xenografts. Histologic examination demonstrated characteristic features of tumor 
angiogenesis with structurally abnormal, tortuous blood vessels in control neuroblastoma xenografts. In contrast, the 
blood vessels observed in tumors, treated with SPARC peptides, were thin walled and structurally more normal. Using a 
novel method to quantitatively assess blood vessel abnormality we demonstrated that both SPARC peptides induced 
changes in blood vessel architecture that are consistent with blood vessel normalization.
Conclusion: Our results demonstrate that SPARC peptide FSEC has potent anti-angiogenic and anti-tumorigenic 
effects in neuroblastoma. Its simple structure and ease of production indicate that it may have clinical utility in the 
treatment of high-risk neuroblastoma and other types of pediatric and adult cancers, which depend on angiogenesis.
Background
Neuroblastoma tumors exhibit a broad spectrum of clini-
cal behavior, reflective of their biologic heterogeneity [1].
Although significant progress has been made in the suc-
cessful treatment of neuroblastoma tumors with favor-
able biology, more effective therapeutic strategies are still
needed for children with high-risk neuroblastoma [2]. A
strong correlation between high-risk tumors and angio-
genesis has been reported by us and other investigators
[3,4], suggesting that blood vessels may be clinically rele-
vant therapeutic targets. In support of this hypothesis,
preclinical studies have demonstrated that neuroblas-
toma tumor growth can be significantly impaired follow-
ing treatment with anti-angiogenic agents [5,6].
The histologic features of neuroblastoma tumors have
also been shown to be prognostic, and an abundance of
Schwannian stroma is associated with a more benign
tumor phenotype and favorable prognosis [7]. Schwann
cells are known to secrete factors that induce neuroblas-
toma differentiation [8,9]. Studies from our laboratory
have demonstrated that Schwann cells also influence
neuroblastoma tumor growth by secreting inhibitors of
angiogenesis [9], the most potent of which is Secreted
Protein Acidic and Rich in Cysteine (SPARC) [10].
SPARC belongs to a group of non-structural components
of the extracellular matrix (ECM) that modulate interac-
tions between cells and their environment [11,12]. It is
highly expressed in a variety of cell types associated with
remodeling tissues [13]. Although the mechanism for its
anti-angiogenic activity is not well understood, SPARC is
capable of interfering with the binding of angiogenic
stimulators vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF), and basic fibro-
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Page 2 of 10blast growth factor (bFGF) to their receptors in endothe-
lial cells, resulting in inhibited proliferation [14]. SPARC
has also been shown to down-regulate VEGF in glioma
cells [15].
The role of SPARC in tumorigenesis appears to be cell-
type specific due to its diverse function in a given
microenvironment [16]. In some types of cancer, high
levels of SPARC expression have been shown to correlate
with disease progression and poor prognosis. In mela-
noma cells, high levels of SPARC expression induce epi-
thelial-mesenchymal transition and increases invasion
and tumor progression [17,18]. High levels of SPARC are
also associated with invasive meningioma [19] and osteo-
sarcoma [20]. In glioma, SPARC promotes invasion, but
delays tumor growth [21]. In other types of cancer,
SPARC functions as a tumor suppressor. It inhibits the
proliferation of breast cancer cells [22] and induces apop-
tosis in ovarian cancer cells [23]. In the majority of pri-
mary lung adenocarcinomas, SPARC silencing is
associated with poor outcome [24]. In non-small cell lung
cancer, SPARC expression is frequently down-regulated
due to methylation of the tumor suppressor RASSF1A
[25]. Similarly, in breast and prostate cancers and neuro-
blastoma, the majority of neoplastic cells do not express
SPARC [12].
Previously, we synthesized peptides corresponding to
the highly conserved structural domains of SPARC and
tested their ability to inhibit angiogenesis [26]. To main-
tain the structural integrity of the native modules,
cysteines within the peptides were linked with disulfide
bonds during the synthesis. Minimal to no inhibitory
activity was observed with the peptides corresponding to
the Kazal module and the α-helix of the EC domain. In
contrast, the epidermal growth factor (EGF)-like module
peptide FS-E strongly inhibited endothelial cell migration
in vitro and angiogenesis in vivo. Reduction of the two
disulfide bonds in the FS-E peptide completely abrogated
the angiogenesis inhibitory effects, indicating that struc-
tural conformation is critical for this biological activity.
We have now designed two additional SPARC peptides
that structurally correspond to N- and C-terminal loops
of the FS-E peptide: FSEN and FSEC, respectively. These
peptides are smaller, less structurally complex, and easier
to produce than the FS-E peptide. We show that both
peptides block angiogenesis, although FSEC is more
potent. We also demonstrate that FSEC effectively inhib-
its neuroblastoma tumor growth in a preclinical model.
Results
Peptide design
Our previous studies demonstrated that peptide FS-E,
representing the N-terminal EGF-like module of the
SPARC follistatin domain, potently inhibits angiogenesis
[26]. This module of SPARC is a β-hairpin, highly twisted
by disulfide bonds that link cysteine 1 to cysteine 3 and
cysteine 2 to cysteine 4. The crystal structure of peptide
FS-E shows that the two central cysteines are closely
located (Figure 1). By linking cysteine 4 with cysteine 3 in
lieu of cysteine 2, separate N- and C-terminal loops of the
peptide can be produced without disturbing the native
structure. Using this strategy, we synthesized the N- and
C-terminal loops of peptide FS-E as two separate pep-
tides, FSEN and FSEC, as detailed in Figure 1. Both pep-
tides were folded into their native conformation by
linking the cysteines that were placed at both ends. In the
FSEN peptide, alanine was substituted for the unpaired
cysteine. Corresponding scrambled control peptides, scF-
SEN and scFSEC that were designed to contain the same
amino acids as peptides FSEN and FSEC in a random
order, were synthesized without special modifications.
Peptides FSEN and FSEC inhibit angiogenesis in vitro and in 
vivo
Migration assays were performed with human umbilical
vein endothelial cells (HUVEC) and each of the synthetic
SPARC peptides to characterize their anti-angiogenic
properties in vitro and to compare their potencies with
the original peptide FS-E. As shown in Figure 2, the C-
terminal loop peptide FSEC inhibited bFGF-stimulated
endothelial cell migration with an EC50 of ~1 pM, which
was even lower than EC50 of ~10 pM of the original FS-E
peptide. Higher concentrations of peptide FSEC did not
inhibit endothelial cell migration, which is also a property
of peptide FS-E [26] and the full-length SPARC [10].
Biphasic inhibition of endothelial cell migration is a char-
acteristic feature of other natural inhibitors of angiogene-
sis, including thrombospondin-1 [27] and endostatin
[28]. The N-terminal loop peptide, FSEN, showed weaker
inhibition of bFGF-stimulated endothelial cell migration,
with an EC50 of ~2 nM. Neither peptide, tested at concen-
trations from 0.1 pM to 100 μM, affected proliferation of
HUVEC cells stimulated with bFGF (data not shown).
Figure 1 SPARC peptides FSEN and FSEC. SPARC peptides FSEN and 
FSEC were designed to correspond to the N-terminal and C-terminal 
loops of peptide FS-E, respectively. The native cysteine linkage was 
preserved in peptide FSEN; the unpaired cysteine was replaced with al-
anine. To maintain the conformation of peptide FSEC, cysteine 4 was 
linked with cysteine 3 instead of cysteine 2.
FS-E
CQNHHCKHGKVCELDENNTPMC
FSEC
CELDENNTPMC
FSEN
CQNHHAKHGKVC
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Page 3 of 10The anti-angiogenic properties of the peptides were
further characterized in vivo using the Matrigel plug
assay. Matrigel plugs containing bFGF and either SPARC
peptides FSEN or FSEC were less hemorrhagic than the
positive control Matrigel plugs containing bFGF with or
without scrambled SPARC peptides (Figure 3A). To
quantify the anti-angiogenic effects of the peptides, we
stained the endothelial cells in paraffin sections of the
Matrigel plugs with green fluorescence using anti-CD31
antibody and visualized the perivascular pericytes with
red fluorescence using anti-α-smooth muscle actin
(SMA) antibody (Figure 3B). The area occupied by each
type of cells was quantified at low magnification in dupli-
cate fields in each sample using ImagePro software. As
shown in Figure 3C, the quantity of CD31-positive
endothelial cells was statistically significantly decreased
in the SPARC peptides-treated Matrigel plugs compared
to the positive controls with bFGF alone (p < 0.005).
Although the area, occupied by SMA-positive pericytes
in the Matrigel plugs containing the SPARC peptides was
significantly smaller compared to the positive controls (p
< 0.005), there was no significant differences in the ratio
of pericytes to endothelial cells (p > 0.8), indicating iden-
tical pericyte coverage. In the Matrigel plugs treated with
Figure 3 Inhibition of neovascularization by peptides FSEN and FSEC in the Matrigel plug assay. (A) Blood vessels developed for 7 days in nude 
mice, injected with Matrigel plugs containing 50 ng/ml bFGF alone (positive control), PBS (negative control), and bFGF with 10 μM SPARC peptides 
FSEN, FSEC, or scrambled control peptides scFSEN and scFSEC. (B) For quantitative analysis of angiogenesis and blood vessel architecture, endothelial 
cells were visualized with green CD31 immunofluorescence, and pericytes were detected with red SMA antibody. Representative photographs at 
×400 magnification are shown. (C) The relative quantity of endothelial cells and pericytes was estimated by calculating the area occupied by green 
and red fluorescence (in pixels). There were statistically significant decreases in the blood vessel area and quantity of pericytes in the Matrigel plugs 
containing SPARC peptides compared to the positive control with bFGF alone (single asterisk) and from the negative control (double asterisk).
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Figure 2 SPARC peptides FSEN and FSEC inhibit endothelial cell migration. HUVEC cells were treated with serial dilutions of SPARC peptides with 
or without 10 ng/ml bFGF in a modified Boyden chamber. Relative stimulation was calculated as percentage of bFGF-induced migration. (A) Peptide 
FSEN inhibited bFGF-stimulated endothelial migration with an EC50 of ~2 nM. (B) Peptide FSEC displayed a strong dose-dependent inhibition of bFGF-
stimulated endothelial migration with an EC50 ~1 pM. Dark circles represent bFGF-stimulated migration; light circles represent basal migration in the 
absence of an activator.
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Page 4 of 10scrambled peptides, no differences in endothelial cell (p >
0.7) or pericyte area (p > 0.3) were detected compared to
the positive controls with bFGF alone.
SPARC peptide FSEC potently inhibits neuroblastoma 
tumor growth
To examine the anti-tumor activity of the SPARC pep-
tides, mice with subcutaneous neuroblastoma xenografts
were treated with either FSEN, FSEC, scrambled peptide
scFSEN, or PBS 5 days/week for 2 weeks. Compared to
control group, statistically significant inhibition of tumor
growth was seen in the animals treated with the FSEC
peptide, but not FSEN (Figure 4). In the FSEC-treated
animals, the average tumor weight at the end of the
experiment was 26% of the weight of the control tumors
(0.38 ± 0.42 g vs 1.48 ± 1.24 g, respectively; p = 0.01). In
the group of animals treated with the peptide FSEN, the
average weight of tumors was 88% of the controls, which
was not statistically significant (1.30 ± 1.77 g, p = 0.83).
The average weight of tumors resected from animals
treated with the scrambled peptide was not different
from the PBS controls (1.51 ± 1 g, p = 0.97).
Vascular architecture was initially evaluated on H&E
stained sections. In the control tumors, the blood vessels
were structurally abnormal with dilated, tortuous appear-
ance and prominent microvascular proliferation (MVP)
(Figure 4C). In xenografts treated with scrambled pep-
tide, a similar architecture was noted with disorganized
layers of endothelial and perivascular cells. Multiple areas
of hemorrhage were present in the control and scrambled
peptide-treated tumors. In the SPARC peptides-treated
tumors, the blood vessel architecture was more normal,
and there was no evidence of hemorrhage or MVP.
Immunofluorescent analysis of the tumors demon-
strated a significant reduction in the quantity of endothe-
lial cells in the SPARC peptide-treated xenografts
compared to controls (Figure 5). The average area occu-
pied by endothelial cells in FSEC-treated xenografts was
13 ± 6% of the blood vessel area in the control xenografts
(5.9 ± 2.6 pixels ×103 vs 44.9 ± 6.6 pixels ×103, respec-
tively; p < 0.001). Peptide FSEN also inhibited angiogene-
sis in the xenografts, although less potently. The average
area occupied by endothelial cells in the FSEN-treated
tumors was 33 ± 9% of the control (15.0 ± 4.0 pixels ×103;
p < 0.001). In contrast, no significant difference in the
quantity of endothelial cells in the xenografts treated with
scrambled peptide or control vehicle was detected (42.4 ±
13.1 pixels ×103, p = 0.67).
The quantity of perivascular cells in each group corre-
sponded to the level of angiogenesis. The average area
occupied by pericytes in the tumors treated with peptides
FSEC vs control tumors was 16 ± 10% (6.2 ± 4.0 pixels
×103 vs 38.6 ± 10.4 pixels ×103, respectively; p < 0.001)
Figure 4 Inhibition of neuroblastoma tumor progression by SPARC peptides FSEN and FSEC in the preclinical model of neuroblastoma. (A) 
Mice with xenografted SMS-KCNR neuroblastoma cells received intraperitoneal injection of PBS, 10 mg/kg of the SPARC peptides FSEN or FSEC, or 
scrambled peptide scFSEN five times a week for 2 weeks. Treatment with the SPARC peptide FSEC resulted in a statistically significant (p < 0.05) de-
crease in the average size of tumors starting from day 4 until the end of the treatment period. The average tumor weight was reduced to 26% (p = 
0.01) of average control tumor weight. The average weight of tumors treated with peptide FSEN was reduced to 88%, but the decrease was not sta-
tistically significant (p = 0.83). Scrambled peptide did not affect tumorigenicity of neuroblastoma xenografts (102%, p = 0.97). (B) Representative pho-
tographs of neuroblastoma tumors treated with the SPARC peptides. (C) Normalization of the blood vessels in the SPARC peptide-treated xenografts. 
H&E staining of areas with large blood vessels at ×200 and ×400 magnification shows areas of extensive hemorrhage and MVP in control tumors and 
tumors treated with the scrambled peptides. In contrast, no evidence of hemorrhage or MVP was seen the SPARC peptide-treated tumors.
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Page 5 of 10and 33 ± 16% (12.8 ± 6.2 pixels ×103; p = 0.004) for pep-
tide FSEN (Figure 5). No difference in the quantity of
pericytes in tumors treated with the scrambled peptide
and controls was detected (40.1 ± 13.1 pixels ×103; p =
0.84). Although pericyte-to-endothelial cell ratio was not
affected by the treatment, differences in the blood vessel
architecture were apparent between the control and
SPARC peptide-treated tumors. In the xenografts treated
with vehicle or scrambled peptide, the blood vessels
exhibited abnormal architecture with multiple layers of
hypertrophic endothelial cells which often lacked co-
localized pericytes. In contrast, blood vessels in the
SPARC peptides-treated tumors had more normal archi-
tecture, mainly consisting of a single layer of spindle-
shaped endothelial cells, enveloped by a layer of pericytes
(Figure 6).
We used a novel approach to quantitatively assess
blood vessel architecture by using 2-dimensional shape
descriptors of Image J software that is similar to the
method, previously described for 3-dimensional shapes
[29]. Circularity is a measure of roundness of an object
with value ranges from 0 to 1, where 1 is a perfect circle.
As shown in Figure 6B, the blood vessels in the peptide-
treated tumors are more circular compared to the PBS
and scrambled peptide-treated controls (Figure 6B).
Aspect ratio reflects the shape of an object as the ratio of
its height to its width. We found that the aspect ratio was
significantly closer to 1 in the treated versus the control
tumors, indicating that these vessels are less elongated.
Solidity, which approximates density of an object, was
appreciably higher in the peptides-treated xenografts,
compared to tumors treated with PBS or scrambled pep-
tide, indicating that the endothelial cells are spaced more
compactly in the blood vessels in the SPARC peptides-
treated tumors. We integrated all three shape descriptors
into a coefficient of abnormality to quantitatively assess
roundness, elongation, and the border shape of the blood
vessels using a scale from 0 to 1, with lower values reflec-
tive of more normal architecture. The scores for the
blood vessels in the tumors treated with peptides FSEN
and FSEC were significantly lower (0.53 ± 0.21 and 0.56 ±
0.20, respectively) compared to the vessels in tumors,
treated with PBS or scrambled peptide (0.88 ± 0.12 and
0.93 ± 0.05, respectively).
Discussion
We have previously shown that full-length SPARC and
SPARC peptide FS-E, that corresponds to the highly con-
served EGF-like module of the follistatin domain,
potently inhibit angiogenesis and neuroblastoma tumor
growth in preclinical models [10,26,30]. The structure of
the FS-E peptide is complex, and we have demonstrated
Figure 5 Inhibition of tumor-induced angiogenesis by peptides FSEN and FSEC in the animal model. For quantitative analysis of angiogenesis 
in the mouse xenografts, paraffin sections were stained with green CD31 and red SMA immunofluorescence. (A) Angiogenesis was quantified by cal-
culating the area occupied by green CD31-positive endothelial cells and red SMA-positive pericytes. The quantity of tumor blood vessels was statis-
tically significantly decreased in the SPARC peptide-treated xenografts compared to vehicle treated control (p < 0.001; marked with an asterisk). 
Treatment with the scrambled peptide did not affect angiogenesis in the xenografted tumors. (B) Representative photographs at ×100 magnification.
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Page 6 of 10that its anti-angiogenic function is conformation-depen-
dent [26]. In an effort to develop a therapeutic that may
be suitable for clinical use, in this study we designed and
synthesized two simply structured derivative peptides,
FSEN and FSEC. Because proper structure is imperative
to maintain activity of the FS-E peptide, peptides FSEN
and FSEC were folded into their native conformation by
linking the end cysteines during synthesis with disulfide
bonds. This was possible due to the close proximity of the
two central cysteines in the FS-E peptide [31]. Linking
cysteine 4 with cysteine 3 instead of cysteine 2 allowed us
to design peptides that correspond to amino acid
sequences in the N- and C-terminal loops without dis-
turbing the native folding. We found that both FSEN and
FSEC function as inhibitors of angiogenesis, although the
FSEC peptide was more potent.
Due to potent anti-angiogenic activity in vitro, a dose of
10 mg/kg was administered 5 days a week to investigate
the effects of SPARC peptides on tumor progression in
the preclinical model. This is a lower amount than the 10
to 100 mg/kg daily doses that have been used to test other
anti-angiogenic peptides in preclinical studies [28,32-35].
At this low dose, peptide FSEC significantly suppressed
neuroblastoma tumor growth in experimental animals.
Furthermore, consistent with properties of SPARC as an
inhibitor of angiogenesis, the number of endothelial and
perivascular cells was also significantly decreased in the
peptide-treated animals, compared to controls.
Although the anti-tumor and anti-angiogenic effects of
peptide FSEN were less potent, both SPARC peptides had
profound effects on the architecture of tumor-induced
blood vessels. In contrast to the structurally abnormal
blood vessels that were seen in the control tumors, thin
walled blood vessels were detected in the peptide-treated
tumors, suggesting that treatment with FSEN and FSEC
induced blood vessel normalization. Interestingly, hem-
orrhage was not detected in the peptide-treated tumors,
whereas significant hemorrhage was detected in the con-
trol tumors.
Similar to the original SPARC peptide FS-E [26], the
proper structural conformation may be essential to main-
tain the anti-angiogenic activity of the FSEC and FSEN
peptides. Disulfide bonds are likely to be unstable in the
reducing environment in vivo, leading to poor pharma-
cokinetic properties and decreased activity of the pep-
tides. Stable analogs of disulfide bonds have been used to
increase activity of other biologically active peptides [36],
and we plan to use this approach to produce more stable
analogs of peptides FSEC and FSEN.
Figure 6 Blood vessel architecture in the peptide-treated murine neuroblastoma xenografts. (A) Endothelial cells and pericytes were visualized 
with green CD31 and red SMA staining respectively. Aberrant blood vessel architecture was evident at ×400 magnification in control xenografts treat-
ed with the vehicle or scrambled peptide. Peptide-treated tumors had more structurally normal, thin-walled blood vessels. (B) Quantitative analysis 
of blood vessel architecture. Circularity estimates roundness of an object, modified aspect ratio measures its elongation, and solidity approximates 
the density. On a scale from 0 to 1, where 1 is a perfect circle, all descriptors were significantly closer to 1 in the SPARC peptide-treated versus the 
control tumors, indicating that blood vessels are more round, less elongated and more compact. Vessel abnormality was calculated as 1 - (circularity 
× aspect ratio × solidity), and was significantly reduced in tumors treated with peptides FSEN and FSEC, showing that treatment induced normaliza-
tion of tumor vasculature. All p-values versus PBS-treated control tumors are shown below the respective bars.
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Page 7 of 10It is well established that cancer blood vessels are not
structurally normal [37]. In tumors, multiple layers of
hypertrophic endothelial cells alternate with areas in
which endothelial cell coverage is lacking. Corresponding
abnormalities in the deposition of the basement mem-
brane are also commonly observed. Perivascular smooth
muscle cells, which provide both mechanical and physio-
logical support for the endothelial monolayer in normal
blood vessels, fail to co-localize with endothelial cells in
neoplastic blood vessels. These abnormalities disrupt the
integrity of the blood vessels, resulting in a heteroge-
neous blood supply of the tumor tissue, vessel leakiness,
and hemorrhage. Our recent evaluation of blood vessel
architecture in a series of neuroblastoma tumors demon-
strated that structurally abnormal blood vessels are com-
monly seen in high-risk tumors, and the presence of MVP
was statistically significantly associated with decreased
survival [38].
Normalization of neoplastic blood vessels has been
demonstrated with other anti-angiogenic therapeutics
[37], and recently the extent of vascular normalization
following treatment with an anti-VEGF therapy was
shown to be predictive of outcome in patients with glio-
blastoma [39]. Emerging evidence also indicates that by
normalizing the abnormal structure and function of
tumor vasculature, anti-angiogenic agents can alleviate
hypoxia and increase the efficacy of conventional thera-
pies [37]. A recently completed phase I dose-escalation
study of an anti-VEGF agent has provided evidence of
both vascular normalization and sensitization of rectal
tumors to radiation [40,41]. Using a simple method to
quantitatively assess blood vessel architecture, we show
that treatment with either FSEC or FSEN similarly nor-
malizes the tumor vasculature. Normalization of blood
vessels may enhance drug delivery to the tumor tissue
and improve efficacy of chemotherapeutic agents. A bet-
ter understanding of the molecular and cellular basis of
vascular normalization may ultimately lead to more effec-
tive strategies for combining chemotherapy and radiation
with agents that are capable of inducing blood vessel nor-
malization.
Conclusion
In summary, we have designed and synthesized SPARC-
derived peptides FSEN and FSEC that are easy to produce
and demonstrated that they function as inhibitors of
angiogenesis in vitro and in vivo. The potent anti-tumor
activity of SPARC peptide FSEC in a preclinical model of
neuroblastoma indicates that it may be an effective treat-
ment for children with high-risk neuroblastoma, as well
as other malignancies. Similar to other anti-angiogenic
agents, the SPARC peptides induced normalization of
blood vessels and thus may enhance drug delivery to the
tumor tissue. Preclinical studies testing the activity of
peptide FSEC in combination with chemotherapy are
planned.
Materials and methods
Peptide synthesis
SPARC peptides FSEN (CQNHHAKHGKVC) and FSEC
(CELDENNTPMC) were synthesized at Alpha Diagnos-
tics International (San Antonio, TX) using fmoc/tboc
chemistry as cyclic cysteine-linked molecules, with disul-
fide bonds unambiguously formed during peptide syn-
thesis. The purity of the peptides was assessed by high-
performance liquid chromatography, and the molecular
mass was checked by mass spectrometry. Control scram-
bled peptides scFSEN (KCGHKHQCAVHN) and scFSEC
(MEPECNLNCTD), which contain the same amino acids
as peptides FSEN and FSEC in a random order, were
made without special modifications.
Cell lines
HUVEC cells (VEC Technologies, Rensselaer, NY) were
maintained at 5% CO2 in EGM media (Lonza, Walkers-
ville, MD) supplemented with 5% FBS (Life Technologies,
Carlsbad, CA). Neuroblastoma cell line SMS-KCNR was
grown at 5% CO2 in RPMI 1640 (Life Technologies) sup-
plemented with 10% heat-inactivated FBS and 1% penicil-
lin/streptomycin.
Endothelial cell migration assay
To characterize the anti-angiogenic properties of the pep-
tides in vitro, migration assays were performed in a mod-
ified Boyden chamber with HUVEC cells in EBM media
(Lonza) containing 0.01% BSA as described [42]. Serial
dilutions of each of the synthetic SPARC peptides, start-
ing at 100 μM were assayed with or without 10 ng/ml
bFGF (National Cancer Institute Preclinical Repository,
Frederick, MD). At least three independent experiments
were performed for each peptide. To compare multiple
experiments, the data were represented as the percentage
of bFGF-induced stimulation using the difference
between bFGF-induced migration and background
migration in EBM alone as 100% control.
Endothelial cell proliferation assay
The effect of SPARC peptides on endothelial cell prolifer-
ation was measured in 96-well plates with HUVEC cells
in EBM media supplemented with 0.5% FBS. Serial ×10
dilutions of SPARC peptides from 0.1 pM to 100 μM with
and without 10 ng/ml bFGF were added to quadruplicate
wells, cells were grown at 37°C in 5% CO2 for 24 and 48 h,
and proliferation was determined with the CellTiter cell
proliferation assay (Promega, Madison, WI).
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Page 8 of 10Matrigel assay
To characterize the anti-angiogenic properties of the pep-
tides in vivo, Matrigel assays were performed in 4- to 6-
week-old homozygous athymic nude mice (Harlan, Madi-
son, WI). SPARC peptides FSEN, FSEC and correspond-
ing scrambled peptides scFSEN and scFSEC were added
to 0.4 ml of Growth Factor-reduced Matrigel (BD Biosci-
ences, Bedford, MA) containing 10 units/ml heparin and
50 ng/ml bFGF to a final concentration of 10 μM. At least
5 animals were subcutaneously injected with Matrigel
plugs containing bFGF and each SPARC peptide. Matri-
gel plugs with bFGF and no peptides served as positive
controls. Matrigels without either bFGF or peptides were
used as negative controls. Mice were sacrificed 7 days
after the Matrigel injections, gels were recovered by dis-
section, photographed, fixed in formaldehyde, and
embedded in paraffin.
Xenograft model
A neuroblastoma xenograft model was used to examine
the anti-tumor activity of peptides FSEN and FSEC.
Briefly, 4-6 week old athymic nude mice were injected
subcutaneously with 0.2 ml PBS containing 1 × 107 SMS-
KCNR neuroblastoma cells. Once tumors were palpable
(~70 mm3), animals were randomized into four treatment
groups with at least 6 animals per group. Experimental
animals received intraperitoneal injection of 10 mg/kg of
the SPARC peptides FSEN or FSEC, or scrambled peptide
scFSEN (0.3 mg of the peptide in 150 μl of PBS) 5 days a
week for 2 weeks. Animals in the control group were
injected with PBS without the peptide. Possible toxic
effects of the treatment were assessed by monitoring the
animals for signs of distress such as difficulty in ambulat-
ing, ulceration, cachexia, respiratory distress, loss of 15-
20% body weight, or gain of 10% body weight. The size of
the tumors was determined every 2-3 days by external
measurements with a caliper. At the end of treatment,
animals were euthanized using CO2 followed by cervical
dislocation. Tumors were removed, measured, weighed,
and photographed. Tissue was fixed with 10% buffered
formalin, embedded in paraffin and 4 μm-thick sections
were prepared for histologic evaluation. All animal stud-
ies were approved by the IACUC at the University of Chi-
cago.
Histological analysis and immunofluorescence
Four-μm-thick sections were stained with H&E for histo-
logical evaluation. The entire tissue section was evaluated
for vascular morphology. Vessels with thickened walls
containing complete layers of hypertrophied endothelial
cells plus additional layers of vascular mural cells were
classified as positive for MVP as previously described
[38]. Vessels with normal vessel architecture and no more
than a single layer of flat, spindle shaped endothelial cells
were characterized as MVP negative. For quantitative
analysis of angiogenesis, 4-μm-thick sections were
stained with anti-CD31 antibody (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA) at a 1:50 dilution followed by
FITC-labeled secondary antibody. To characterize the
blood vessel architecture, pericytes were visualized with
red fluorescence using anti-α-SMA antibody (Sigma-
Aldrich, St. Louis, MO) at 1:100 dilution. The area occu-
pied by each cell type was quantified at ×100 magnifica-
tion in duplicate fields in each sample using ImagePro
software. Two-dimensional shape descriptors of Image J
software were used to quantitatively assess blood vessel
architecture. Circularity was calculated as 4π × area/
perimeter2, modified aspect ratio was measured as
object's width/length, and solidity was calculated as a
ratio of an object area/convex hull (outermost outline).
Coefficient of abnormality was calculated as 1 - (circular-
ity × aspect ratio × solidity).
Statistical analysis
All in vitro experiments were repeated at least in tripli-
cates and standard deviations were calculated. All animal
studies had at least 5 mice per group and mean values of
the tumor volumes, weights, and vessel densities were
compared. All the quantitative values obtained in the
experiments were evaluated using paired Student's t-test.
A p-value of 0.05 was required to ascertain statistical sig-
nificance.
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